title: Monoclonal antibodies: magic bullets with a hefty price tag.
authors.affiliation: Tufts University School of Medicine, Boston, Massachusetts, USA. Allen.Shaughnessy@Tufts.edu
authors.forename: Allen F
authors.initials: AF
authors.lastname: Shaughnessy
mesh_terms: D000074323:Alemtuzumab; D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D004345:Drug Industry; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008268:Macular Degeneration / Q000188:drug therapy; D009103:Multiple Sclerosis / Q000188:drug therapy; D056687:Off-Label Use; D009894:Opportunistic Infections / Q000209:etiology; D000069579:Ranibizumab
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000074323:Alemtuzumab; D000069579:Ranibizumab